Dermatol. praxi. 2019;13(1):26-28 | DOI: 10.36290/der.2019.005

Secukinumab in the treatment of severe form of psoriasis

MUDr. Jan Šternberský, Ph.D., MUDr. Martin Tichý, Ph.D.
Klinika chorob kožních a pohlavních LF UP a FN Olomouc

Secukinumab belongs to the type of treatment called biologics, products of biotechnological engineering. I tis fully humanized
antibody against interleukin 17A, which play one of the key roles in the pathogenesis of psoriasis. Secukinumab is indicated for
the treatment of severe forms of psoriasis, which are characterised by values of PASI > 10. Secukinumab has got very fast onset
of effect, excellent therapeutic response and up to date safety data are also very favorable. The case report describes excellent
effect of secukinumab in the treatment of severe form of psoriasis in an older man

Keywords: secukinumab, psoriasis, interleukin 17 A.

Published: March 21, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šternberský J, Tichý M. Secukinumab in the treatment of severe form of psoriasis. Dermatol. praxi. 2019;13(1):26-28. doi: 10.36290/der.2019.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17 A biologic for the treatment of psoriasis. Ther Adv Chronic, DiS. 2018 Jan; 9(1): 5-21. Go to original source... Go to PubMed...
    2. Hercogová J. Léčba psoriázy v dermatologické praxi. Čes. Dermatovenerol. 2018; 8: 47-51
    3. Cetkovska P et al. Přehled současných doporučených postupů pro systémovou "nebiologickou" léčbu psoriázy. Čes-slov Derm 2017; 92: 1-52
    4. Puig L. The role of biologics in the treatment of moderate-to-severe plaque psoriasis. G Ital Dermatol Venereol. 2017 Feb; 152(1): 28-35. Go to original source...
    5. Dogra S, Krishna V, Kanwar AJ. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol. 2012 Oct; 37(7): 729-734. Go to original source... Go to PubMed...
    6. Borghi A, Corazza M, Bertoldi AM, Caroppo F, Virgili A. Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety. Acta Derm Venereol. 2015 Mar;95(3): 332-336. Go to original source... Go to PubMed...
    7. Singh K, Argáez C. Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Apr 3.
    8. Reich, K., Blauvelt, A, Krueger, J, et al., Candidiasis in Secukinumab-Treated Patients Is Non-serious and Transient: A Pooled Analysis of Data from 10 Phase 2 and 3 Clinical Trials in Psoriasis. Federation of Clinical Immunology Societes (FOCIS) Annual Meeting; 25-28 June 2014 Chicago Illinois USA: 2014 2014
    9. Mease PJ, McInnes IB, Reich K, Andersson M, Tao A, Fox T, Karyekar C. Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10) Go to original source...
    10. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 Sep; 32(9): 1507-1514. Go to original source... Go to PubMed...
    11. Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3 b study. J Am Acad Dermatol. 2017 Oct; 77(4): 667-674. Go to original source... Go to PubMed...
    12. Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M. Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2018 Oct 26 Go to original source... Go to PubMed...
    13. Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, Hugot S, Milutinovic M. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017 Jan; 76(1): 70-80. Go to original source... Go to PubMed...
    14. Thaci, D., et al., Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol, 2015. Go to original source... Go to PubMed...
    15. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014; 371(4): 326-338. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.